Amlodipine and valsartan as components of a rational and effective fixed-dose combination.

Fiche du document

Auteurs
Date

2009

Types de document
Périmètre
Langue
Identifiant
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/19436661

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1178-2048[electronic]

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_F0D25C6C63EC3

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer

Mots-clés 0

Age Factors; Aged; Amlodipine/adverse effects; Amlodipine/therapeutic use; Angiotensin II Type 1 Receptor Blockers/adverse effects; Angiotensin II Type 1 Receptor Blockers/therapeutic use; Antihypertensive Agents/therapeutic use; Blood Pressure/drug effects; Calcium Channel Blockers/adverse effects; Calcium Channel Blockers/therapeutic use; Diuretics/therapeutic use; Drug Combinations; Humans; Hypertension/drug therapy; Hypertension/physiopathology; Medication Adherence; Middle Aged; Tetrazoles/adverse effects; Tetrazoles/therapeutic use; Treatment Outcome

Sujets proches En

Therapy

Citer ce document

B. Waeber et al., « Amlodipine and valsartan as components of a rational and effective fixed-dose combination. », Serveur académique Lausannois, ID : 10670/1.n1t80c

Métriques

Partage / Export

Résumé 0

Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications. Calcium antagonists and blockers of the renin-angiotensin system are widely used today to initiate antihypertensive therapy but, when given as monotherapy, do not suffice in most patients to normalize blood pressure. Combining the two types of agents considerably increases the antihypertensive efficacy, but not at the expense of a deterioration of tolerability. This is exemplified by the experience accumulated with the recently developed fixed dose combination containing the AT(1)-receptor blocker valsartan (160 mg) and the dihydropyridine amlodipine (5 or 10 mg). In a randomized trial, an 8-week treatment normalized blood pressure (

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en